Nitroglycerin
Product Description
Osmopharm S.A.
-
CH -
2015On CPHI since
Specifications
Osmopharm S.A.
-
CH
-
2015On CPHI since
More Products from Osmopharm S.A. (99)
-
Product Meclozine
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes meclozine. It belongs to anti emetic / antihistaminic category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Naftohydrofuryl oxalate
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes naftohydrofuryl oxalate. It belongs to vasodilator category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Nicardipina
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes nicardipina. It belongs to antianginal / antihypertensive category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Nifedipine
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes nifedipine. It belongs to antianginal / antihypertensive category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Nifedipine + Atenolol
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes nifedipine + atenolol. It is a pharmaceutical association. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Nitrofurantoin
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes nitrofurantoin. It belongs to antibacteral category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Norphenephrine HCI
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes norphenephrine HCI. It is used for treatment of hipotensive states. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Nylidrin / Buphenine
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes nylidrin / buphenine. It belongs to vasodilator category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Omeprazolo
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes omeprazolo. It belongs to antiulcerative category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Oxazepam
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes oxazepam. It belongs to anxiolytic category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Oxeladine Citrate
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes oxeladine citrate. It belongs to antitussive category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information. -
Product Pancreatine
Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes pancreatine. It belongs to digestive aid category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance